

General information about company		
Scrip code*	524502	
NSE Symbol*	NOTLISTED	
MSEI Symbol*	NOTLISTED	
ISIN*	INE548H01015	
Name of company	RAAJ MEDISAFE INDIA LIMITED	
Type of company	Main Board	
Class of security	Equity	
Date of start of financial year	01-04-2025	
Date of end of financial year	31-03-2026	
Date of board meeting when results were approved	29-05-2026	
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	20-05-2026	
Description of presentation currency	INR	
Level of rounding	Lakhs	
Reporting Type	Quarterly	
Reporting Quarter	Fourth quarter	
Nature of report standalone or consolidated	Standalone	
Whether results are audited or unaudited for the quarter ended	Audited	
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited	
Segment Reporting	Multi segment	
Description of single segment		
Start date and time of board meeting	29-05-2026 15:00	
End date and time of board meeting	29-05-2026 17:00	
Whether cash flow statement is applicable on company	Yes	
Type of cash flow statement	Cash Flow Indirect	
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion	
Whether the company has any related party?	Yes	
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes	
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA	
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA	
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No	
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?		
(b) If answer to above question is No, please explain the reason for not complying.		
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes	
Latest Date on which RPT policy is updated	08-04-2024	
Indicate Company website link for updated RPT policy of the Company	www.raajmedisafeindia.com	
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	Yes	
No. of times funds raised during the quarter	1	
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No	1

Financial Results – Ind-AS				
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)	
Date of start of reporting period		01-01-2026	01-04-2025	
Date of end of reporting period		31-03-2026	31-03-2026	
Whether results are audited or unaudited		Audited	Audited	
Nature of report standalone or consolidated		Standalone	Standalone	
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.			
1	Income			
	Revenue from operations	2507.68	8001.46	
	Other income	28.16	56.31	
	Total income	2535.84	8057.77	
2	Expenses			
(a)	Cost of materials consumed	1541.13	5268.56	
(b)	Purchases of stock-in-trade	0	0	
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	133.08	-120.97	
(d)	Employee benefit expense	108.39	510.34	
(e)	Finance costs	107.97	396.32	
(f)	Depreciation, depletion and amortisation expense	62.5	204.16	
(g)	Other Expenses			
1	Manufacturing, Office and Admin. Expenses	454.15	1167.13	
	Total other expenses	454.15	1167.13	
	Total expenses	2407.22	7425.54	
3	Total profit before exceptional items and tax	128.62	632.23	
4	Exceptional items	0	0	
5	Total profit before tax	128.62	632.23	
6	Tax expense			
7	Current tax	105.53	105.53	
8	Deferred tax	345.72	345.73	
9	Total tax expenses	451.25	451.26	
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0	
11	Net Profit Loss for the period from continuing operations	-322.63	180.97	
12	Profit (loss) from discontinued operations before tax	0	0	
13	Tax expense of discontinued operations	0	0	
14	Net profit (loss) from discontinued operation after tax	0	0	
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0	
16	Total profit (loss) for period	-322.63	180.97	
17	<u>Other comprehensive income net of taxes</u>	0	0	
18	Total Comprehensive Income for the period	-322.63	180.97	
19	Total profit or loss, attributable to			
	Profit or loss, attributable to owners of parent			
	Total profit or loss, attributable to non-controlling interests			
20	Total Comprehensive income for the period attributable to			
	Comprehensive income for the period attributable to owners of parent			
	Total comprehensive income for the period attributable to owners of parent non-controlling interests			
21	Details of equity share capital			

	Paid-up equity share capital	1642.43	1642.43	
	Face value of equity share capital	3031.58	3031.58	
22	Reserves excluding revaluation reserve		0	
23	Earnings per share			
i	Earnings per equity share for continuing operations			
	Basic earnings (loss) per share from continuing operations	-1.96	1.1	
	Diluted earnings (loss) per share from continuing operations	-1.96	1.1	
ii	Earnings per equity share for discontinued operations			
	Basic earnings (loss) per share from discontinued operations	0	0	
	Diluted earnings (loss) per share from discontinued operations	0	0	
iii	Earnings per equity share (for continuing and discontinued operations)			
	Basic earnings (loss) per share from continuing and discontinued operations	-1.96	1.1	
	Diluted earnings (loss) per share from continuing and discontinued operations	-1.96	1.1	
24	Debt equity ratio			Textual Information(1)
25	Debt service coverage ratio			Textual Information(2)
26	Interest service coverage ratio			Textual Information(3)
27	Disclosure of notes on financial results	Textual Information(4)		

Statement of Asset and Liabilities		
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2025
Date of end of reporting period		31-03-2026
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Standalone
	Assets	
1	Non-current assets	
	Property, plant and equipment	3829.8
	Capital work-in-progress	2676.48
	Investment property	
	Goodwill	0
	Other intangible assets	0
	Intangible assets under development	74.56
	Biological assets other than bearer plants	
	Investments accounted for using equity method	
	Non-current financial assets	
	Non-current investments	7.3
	Trade receivables, non-current	
	Loans, non-current	422.24
	Other non-current financial assets	
1	Other non-current financial assets	79.31
2		
3		
4		
5		
	Details of other non-current financial assets	
	Total of other non-current financial assets	79.31
	Total non-current financial assets	508.85
	Deferred tax assets (net)	
	Other non-current assets	
1		
2		
3		
4		
5		
	Details of other non-current assets	
	Total of other non-current assets	
	Total non-current assets	7089.69
2	Current assets	
	Inventories	1488.65
	Current financial asset	
	Current investments	0
	Trade receivables, current	1175.46
	Cash and cash equivalents	1245.99
	Bank balance other than cash and cash equivalents	55.04
	Loans, current	0
	Other current financial assets	
1		
2		
3		

4		
5		
	Details of other current financial assets	
	Total of Other current financial assets	
	Total current financial assets	2476.49
	Current tax assets (net)	
	Other current assets	
1	Other current assets	1080.04
2		
3		
4		
5		
	Details of other current assets	
	Total of other current assets	1080.04
	Total current assets	5045.18
3	Non-current assets classified as held for sale	
4	Regulatory deferral account debit balances and related deferred tax Assets	
	Total assets	12134.87
	Equity and liabilities	
1	Equity	
	Equity attributable to owners of parent	
	Equity share capital	1642.43
	Other equity	3031.58
	Total equity attributable to owners of parent	4674.01
	Non controlling interest	
	Total equity	4674.01
2	Liabilities	
	Non-current liabilities	
	Non-current financial liabilities	
	Borrowings, non-current	3648.83
	Trade Payables, non-current	
	(A) Total outstanding dues of micro enterprises and small enterprises	
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	
	Total Trade payable	
	Other non-current financial liabilities	
1		
2		
3		
4		
5		
	Details of other non-current financial liabilities	
	Total of other non-current financial liabilities	
	Total non-current financial liabilities	3648.83
	Provisions, non-current	3
	Deferred tax liabilities (net)	229.91
	Deferred government grants, Non-current	
	Other non-current liabilities	
1	Lease Liabilities	48.28
2		
3		
4		
5		

	Details of other non-current liabilities	
	Total of other non-current liabilities	48.28
	Total non-current liabilities	3930.02
	Current liabilities	
	Current financial liabilities	
	Borrowings, current	2764.25
	Trade Payables, current	
	(A) Total outstanding dues of micro enterprises and small enterprises	0
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	505.13
	Total Trade payable	505.13
	Other current financial liabilities	
1	Lease Liabilities	5.77
2		
3		
4		
5		
	Details of other current financial liabilities	
	Total of other current financial liabilities	5.77
	Total current financial liabilities	3275.15
	Other current liabilities	
1	Other current liabilities	49.13
2		
3		
4		
5		
	Details of other current liabilities	
	Total of other current liabilities	49.13
	Provisions, current	101.03
	Current tax liabilities (Net)	105.53
	Deferred government grants, Current	
	Total current liabilities	3530.84
3	Liabilities directly associated with assets in disposal group classified as held for sale	
4	Regulatory deferral account credit balances and related deferred tax liability	
	Total liabilities	7460.86
	Total equity and liabilities	12134.87
	Disclosure of notes on assets and liabilities	

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results			
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-01-2026	01-04-2025
Date of end of reporting period		31-03-2026	31-03-2026
Whether results are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Standalone	Standalone
1	Segment Revenue (Income)		
	(net sale/income from each segment should be disclosed)		
1	PLASTIC	1534.62	5403.21
2	HYGIENE	1001.22	2654.57
	Total Segment Revenue	2535.84	8057.78
	Less: Inter segment revenue	1.48	5.36
	Revenue from operations	2534.36	8052.42
2	Segment Result		
	Profit (+) / Loss (-) before tax and interest from each segment		
1	PLASTIC	105.96	626.7
2	HYGIENE	172.22	598.85
	Total Profit before tax	278.18	1225.55
	i. Finance cost	107.05	395.4
	ii. Other Unallocable Expenditure net off Unallocable income	42.51	197.92
	Profit before tax	128.62	632.23
3	(Segment Asset - Segment Liabilities)		
	Segment Asset		
1	PLASTIC	7112.44	7112.44
2	HYGIENE	4915.86	4915.86
	Total Segment Asset	12028.3	12028.3
	Un-allocable Assets	106.57	106.57
	Net Segment Asset	12134.87	12134.87
4	Segment Liabilities		
	Segment Liabilities		
1	PLASTIC	5262.19	5262.19
2	HYGIENE	4921.19	4921.19
	Total Segment Liabilities	10183.38	10183.38
	Un-allocable Liabilities	1951.49	1951.49
	Net Segment Liabilities	12134.87	12134.87
	Disclosure of notes on segments		

Other Comprehensive Income			
Date of start of reporting period		01-01-2026	01-04-2025
Date of end of reporting period		31-03-2026	31-03-2026
Whether results are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Standalone	Standalone
	Other comprehensive income [Abstract]		
1	Amount of items that will not be reclassified to profit and loss		
	Total Amount of items that will not be reclassified to profit and loss		
2	Income tax relating to items that will not be reclassified to profit or loss		
3	Amount of items that will be reclassified to profit and loss		
	Total Amount of items that will be reclassified to profit and loss		
4	Income tax relating to items that will be reclassified to profit or loss		
5	Total Other comprehensive income		

Cash flow statement, indirect		
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2025
Date of end of reporting period		31-03-2026
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Standalone
Part I	Blue color marked fields are non-mandatory.	
1	Statement of cash flows	
	Cash flows from used in operating activities	
	Profit before tax	632.23
2	Adjustments for reconcile profit (loss)	
	Adjustments for finance costs	0
	Adjustments for decrease (increase) in inventories	-674.42
	Adjustments for decrease (increase) in trade receivables, current	494.05
	Adjustments for decrease (increase) in trade receivables, non-current	0
	Adjustments for decrease (increase) in other current assets	-608.43
	Adjustments for decrease (increase) in other non-current assets	0
	Adjustments for other financial assets, non-current	0
	Adjustments for other financial assets, current	-12.39
	Adjustments for other bank balances	0
	Adjustments for increase (decrease) in trade payables, current	75.84
	Adjustments for increase (decrease) in trade payables, non-current	0
	Adjustments for increase (decrease) in other current liabilities	-132.41
	Adjustments for increase (decrease) in other non-current liabilities	0
	Adjustments for depreciation and amortisation expense	204.16
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0
	Adjustments for provisions, current	50.83
	Adjustments for provisions, non-current	0
	Adjustments for other financial liabilities, current	0
	Adjustments for other financial liabilities, non-current	0
	Adjustments for unrealised foreign exchange losses gains	0
	Adjustments for dividend income	0
	Adjustments for interest income	-396.32
	Adjustments for share-based payments	0
	Adjustments for fair value losses (gains)	0
	Adjustments for undistributed profits of associates	0
	Other adjustments for which cash effects are investing or financing cash flow	0
	Other adjustments to reconcile profit (loss)	0
	Other adjustments for non-cash items	0.05
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
	Total adjustments for reconcile profit (loss)	-206.4
	Net cash flows from (used in) operations	425.83
	Dividends received	0
	Interest paid	0
	Interest received	-59.34
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) operating activities	366.49
3	Cash flows from used in investing activities	
	Cash flows from losing control of subsidiaries or other businesses	0

	Cash flows used in obtaining control of subsidiaries or other businesses	0
	Other cash receipts from sales of equity or debt instruments of other entities	0
	Other cash payments to acquire equity or debt instruments of other entities	0
	Other cash receipts from sales of interests in joint ventures	0
	Other cash payments to acquire interests in joint ventures	0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
	Proceeds from sales of property, plant and equipment	0
	Purchase of property, plant and equipment	3349.71
	Proceeds from sales of investment property	0
	Purchase of investment property	0
	Proceeds from sales of intangible assets	0
	Purchase of intangible assets	0
	Proceeds from sales of intangible assets under development	0
	Purchase of intangible assets under development	0
	Proceeds from sales of goodwill	0
	Purchase of goodwill	0
	Proceeds from biological assets other than bearer plants	0
	Purchase of biological assets other than bearer plants	0
	Proceeds from government grants	0
	Proceeds from sales of other long-term assets	0
	Purchase of other long-term assets	79.31
	Cash advances and loans made to other parties	-1199.91
	Cash receipts from repayment of advances and loans made to other parties	0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
	Dividends received	0
	Interest received	59.34
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) investing activities	-2169.77
4	Cash flows from used in financing activities	
	Proceeds from changes in ownership interests in subsidiaries	0
	Payments from changes in ownership interests in subsidiaries	0
	Proceeds from issuing shares	324.57
	Proceeds from issuing other equity instruments	1476.92
	Payments to acquire or redeem entity's shares	0
	Payments of other equity instruments	0
	Proceeds from exercise of stock options	0
	Proceeds from issuing debentures notes bonds etc	0
	Proceeds from borrowings	1637.2
	Repayments of borrowings	0
	Payments of lease liabilities	-53.55
	Dividends paid	0
	Interest paid	396.32
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	1.88
	Net cash flows from (used in) financing activities	3097.8
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	1294.52
5	Effect of exchange rate changes on cash and cash equivalents	
	Effect of exchange rate changes on cash and cash equivalents	0
	Net increase (decrease) in cash and cash equivalents	1294.52

	Cash and cash equivalents cash flow statement at beginning of period	6.49
	Cash and cash equivalents cash flow statement at end of period	1301.01

Format for Disclosure of Related Party Transactions (applicable only for half-year)

Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case of party of the
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary								Open balance
1	Raaj Medisafe India Limited	AABCM1901C	Shriji Polymers (India) Limited	AAICS6990E	Shri Arpit Bangur through his relatives as shareholder	Sale of goods or services		1400	YES	1200	11-08-2025	1063.38	84.11
2	Raaj Medisafe India Limited	AABCM1901C	Shriji Polymers (India) Limited	AAICS6990E	Shri Arpit Bangur through his relatives as shareholder	Purchase of goods or services		100	YES	200	11-08-2025	73.32	17.60
3	Raaj Medisafe India Limited	AABCM1901C	Shree Packers (MP) Private Limited	AAOCS8057N	Shri Arpit Bangur is a Director and himself and relatives are shareholders	Sale of goods or services		150	YES			108.67	10.29
4	Raaj Medisafe India Limited	AABCM1901C	Shree Packers (MP) Private Limited	AAOCS8057N	Shri Arpit Bangur is a Director and himself and relatives are shareholders	Purchase of goods or services		50	YES			14.23	0
5	Raaj Medisafe India Limited	AABCM1901C	Vyanktresh Corrugators Private Limited	AABCG9698L	Shri Arpit Bangur through his relatives as shareholder	Sale of goods or services		10	YES			0.18	3.13
6	Raaj Medisafe India Limited	AABCM1901C	Shrinivas Polyfabrics & Packwell Private Limited	AARCS5889F	Shri Arpit Bangur through his relatives as shareholder	Sale of goods or services		1600	YES	1400	11-08-2025	1651.28	109.00
7	Raaj Medisafe India Limited	AABCM1901C	Shrinivas Polyfabrics & Packwell Private Limited	AARCS5889F	Shri Arpit Bangur through his relatives as shareholder	Purchase of goods or services		0	YES	200	11-08-2025	148.36	0
8	Raaj Medisafe India Limited	AABCM1901C	Narsing Transport	AAHFN3084A	Shri Arpit Bangur through his relatives as shareholder	Purchase of fixed assets		40	YES			26.47	0.79
9	Raaj Medisafe India Limited	AABCM1901C	Parekhplast India Limited	AABCP4523B	Shri Arpit Bangur through his relatives as shareholder	Sale of goods or services		150	YES			131.09	34.18
10	Raaj Medisafe India Limited	AABCM1901C	Four M Propack Private Limited	AABCF2676H	Shri Arpit Bangur through his relatives as shareholder	Sale of goods or services		150	YES			111.69	11.60
11	Raaj Medisafe India Limited	AABCM1901C	Four M Propack Private Limited	AABCF2676H	Shri Arpit Bangur through his relatives as shareholder	Purchase of goods or services		150	YES			64.46	49.60

12	Raaj Medisafe India Limited	AABCM1901C	Four M Propack Private Limited	AABCF2676H	Shri Arpit Bangur through his relatives as shareholder	Purchase of fixed assets		150	YES			93.46	0
13	Raaj Medisafe India Limited	AABCM1901C	Vyanktesh Corrugators Private Limited	AABCG9698L	Shri Arpit Bangur through his relatives as shareholder	Purchase of goods or services		20	YES			12.18	0
14	Raaj Medisafe India Limited	AABCM1901C	Shriniwas Pharmachem Private Limited	ABDCS7715H	Shri Arpit Bangur through his relatives as shareholder	Sale of goods or services		50	YES			0.03	0.03
15	Raaj Medisafe India Limited	AABCM1901C	Shriniwas Polyfabrics & Packwell Private Limited	AARCS5889F	Shri Arpit Bangur through his relatives as shareholder	Interest received		0	YES			5.25	296.8
Total value of transaction during the reporting period												3504.05	

Details of Impact of Audit Qualification			
Whether results are audited or unaudited		Audited	
Declaration of unmodified opinion or statement on impact of audit qualification		Declaration of unmodified opinion	
Auditor's opinion			
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results		Yes	
	Audit firm's name	Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI	Certificate valid upto
1	GDK & ASSOCIATES	Yes	30-06-2026

Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)	
Mode of Fund Raising	Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)	
Date of Raising Funds	26-03-2026
Amount Raised	180125000
Report filed for Quarter ended	31-03-2026
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	
If Yes, Date of shareholder Approval	
Explanation for the Deviation / Variation	
Comments of the Audit Committee after review	None
Comments of the auditors, if any	None

Signatory Details	
Name of signatory	ARPIT BANGUR
Designation of person	Managing Director
Place	UJJAIN
Date	29-05-2026

